{"product_id":"global-adalimumab-monoclonal-antibody-biosimilar-market-growth-2023-2029","title":"Global Adalimumab Monoclonal Antibody Biosimilar Market Growth 2023-2029","description":"\u003cp\u003eGlobal Adalimumab Monoclonal Antibody Biosimilar Market Growth 2023-2029\u003cbr\u003e\nThe global Adalimumab Monoclonal Antibody Biosimilar market size is projected to grow from US$ 411.8 million in 2022 to US$ 966.9 million in 2029; it is expected to grow at a CAGR of 13.0% from 2023 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eThe introduction of Humira biosimilars is expected to increase competition in the market, leading to lower prices and improved access to treatment for patients. The availability of biosimilars provides an alternative option for healthcare providers and payers to choose from, potentially reducing the overall healthcare expenditure associated with biologic treatments.\u003c\/p\u003e\n\n\u003cp\u003eAdalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.\u003c\/p\u003e\n\n\u003cp\u003eLPI (LP Information)' newest research report, the “Adalimumab Monoclonal Antibody Biosimilar Industry Forecast” looks at past sales and reviews total world Adalimumab Monoclonal Antibody Biosimilar sales in 2022, providing a comprehensive analysis by region and market sector of projected Adalimumab Monoclonal Antibody Biosimilar sales for 2023 through 2029. With Adalimumab Monoclonal Antibody Biosimilar sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Adalimumab Monoclonal Antibody Biosimilar industry.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report provides a comprehensive analysis of the global Adalimumab Monoclonal Antibody Biosimilar landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Adalimumab Monoclonal Antibody Biosimilar portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Adalimumab Monoclonal Antibody Biosimilar market.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Adalimumab Monoclonal Antibody Biosimilar and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Adalimumab Monoclonal Antibody Biosimilar.\u003c\/p\u003e\n\n\u003cp\u003eThis report presents a comprehensive overview, market shares, and growth opportunities of Adalimumab Monoclonal Antibody Biosimilar market by product type, application, key manufacturers and key regions and countries.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by type\u003cbr\u003e\nSyringe\u003cbr\u003e\nPen\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by application\u003cbr\u003e\nAnkylosing Spondylitis\u003cbr\u003e\nRheumatoid Arthritis\u003cbr\u003e\nCrohn’s Disease\u003cbr\u003e\nOther\u003c\/p\u003e\n\n\u003cp\u003eThis report also splits the market by region:\u003cbr\u003e\nAmericas\u003cbr\u003e\nUnited States\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\nBrazil\u003cbr\u003e\nAPAC\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nKorea\u003cbr\u003e\nSoutheast Asia\u003cbr\u003e\nIndia\u003cbr\u003e\nAustralia\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUK\u003cbr\u003e\nItaly\u003cbr\u003e\nRussia\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003cbr\u003e\nEgypt\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nIsrael\u003cbr\u003e\nTurkey\u003cbr\u003e\nGCC Countries\u003c\/p\u003e\n\n\u003cp\u003eThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\nCadila Healthcare\u003cbr\u003e\nTorrent Pharmaceuticals\u003cbr\u003e\nAmgen\u003cbr\u003e\nBoehringer Ingelheim\u003cbr\u003e\nNovartis\u003cbr\u003e\nSamsung Bioepis\u003cbr\u003e\nViatris\u003cbr\u003e\nPfizer\u003cbr\u003e\nFresenius Kabi\u003cbr\u003e\nCoherus\u003c\/p\u003e\n\n\u003cp\u003eKey Questions Addressed in this Report\u003c\/p\u003e\n\n\u003cp\u003eWhat is the 10-year outlook for the global Adalimumab Monoclonal Antibody Biosimilar market?\u003c\/p\u003e\n\n\u003cp\u003eWhat factors are driving Adalimumab Monoclonal Antibody Biosimilar market growth, globally and by region?\u003c\/p\u003e\n\n\u003cp\u003eWhich technologies are poised for the fastest growth by market and region?\u003c\/p\u003e\n\n\u003cp\u003eHow do Adalimumab Monoclonal Antibody Biosimilar market opportunities vary by end market size?\u003c\/p\u003e\n\n\u003cp\u003eHow does Adalimumab Monoclonal Antibody Biosimilar break out type, application?\u003c\/p\u003e\n\n\u003cp\u003eWhat are the influences of COVID-19 and Russia-Ukraine war?\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"June, 2023 \/ 104 Pages \/ MCW16230384","offer_id":47647068979506,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-adalimumab-monoclonal-antibody-biosimilar-market-growth-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}